12 results
Thumbnail

D1.102 - Md

Thumbnail

D1.88 - Mepolizumab and intestinal parasitic infection: A case report

Thumbnail

D1.91 - Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)

Thumbnail

D1.93 - ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up

Thumbnail

D1.94 - Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients

Thumbnail

D1.95 - Dupilumab-induced eosinophilia: a transient effect

Thumbnail

D1.96 - Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)

Thumbnail

D1.99 - Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP

Thumbnail

D1.343 - Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis

Thumbnail

D1.345 - Biologic Agents in Neurosarcoidosis: Efficacy and Future Perspectives from a Single-Center Cohort Study

Thumbnail

D1.350 - A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes

Thumbnail

D1.353 - When eosinophils surpass the limits without a known cause